Trazodone FDA Approval History: Label, Safety, and Regulatory Timeline
Trazodone's FDA label lists QT prolongation as a precaution, not a boxed warning: use caution with other QT-prolonging drugs, bradycardia or hypokalemia.
Trazodone: Regulatory History
4 source-based articles maintained by the HealthRX.com Editorial Team.
4articles
2topic areas covered
Jan 30, 2025latest review
Trazodone: Regulatory History library
Showing 4 of 4 clinical reviews.
Trazodone Global Regulatory Status: FDA Approval, International Labels, and Post-Market Safety
A complete review of trazodone's regulatory history across FDA, EMA, and global agencies, including approval timelines, labeling updates, and post-market safety surveillance data.
Trazodone Label Updates 2020-2026: FDA Safety Revisions, Boxed Warnings, and Post-Market Changes
A comprehensive review of trazodone FDA label updates from 2020 through 2026, covering revised warnings, post-market safety data, boxed warning modifications, and clinical guidance changes.
Trazodone: EMA vs FDA Regulatory Approach
A detailed comparison of how the FDA and EMA regulate trazodone, covering approved indications, labeling differences, safety warnings, and post-market surveillance strategies.